Promising Platform for Cancer Immunotherapy

Celldex has flipped Dendreon's biological model on its head. With a goal of specifically and efficiently targeting a subset of immune cells in vivo, Celldex designed antibodies that bind to the internalization receptor (the DEC-205 receptor) on APCs, and are also tethered to the cancer antigen. The APC internalizes the antibody/antigen complex, and can then signal to T-cells to begin the assault on cancerous tissue. This method has the benefits of classical vaccines, as well as the specificity and efficiency of Dendreon's Provenge, with a fraction of the cost.

A Promising Platform for Cancer Immunotherapy - BMY, CLDX, DNDN, MRK - Foolish Blogging Network

No comments: